Conatus Pharmaceuticals Raises $7.5M; Closes $32.5M Series B Financing
Summary
Conatus Pharmaceuticals Inc., a San Diego, CA-based biopharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology, has received an additional $7.5m investment by MPM Capital, closing its Series B round at $32.5m., a San Diego, CA-based biopharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology, has received an additional $7.5m investment by, closing itsround at $32.5m.The first closing was held in early February, 2011 ( see news ).In conjunction with the investment, Jim Scopa from MPM will join Conatus’ Board of Directors.The company will use the proceeds to advance the clinical development of CTS-1027, a novel clinical-stage drug candidate it licensed from F. Hoffman-La Roche, Ltd. and the subject of multiple Phase 2 clinical trials in hepatitis C (HCV)-infected patients.